

28 October 2016

Arthrem® osteoarthritis follow-up trial result published in the New Zealand Medical Journal

The directors of Promisia Integrative Limited, announced today that results of the Otago University's Dunedin School of Medicine's 6-month extension study of Arthrem® have been published in the peer-reviewed *New Zealand Medical Journal*, the official journal of the New Zealand Medical Association.

The extension study follows a previously published 12-week double-blind, randomised, placebo-controlled clinical trial of the plant-based dietary supplement Arthrem® in patients with osteoarthritis of the hip or knee. That study showed Arthrem® treatment to be associated with significant pain reduction over 12 weeks. The extension study's aim was to assess the longer term safety and efficacy of Arthrem® during an additional 6 months' treatment. The trial involved safety and efficacy assessments at 3 and 6 months.

The results of the trial were extremely positive. There was sustained efficacy and clinically relevant improvements in function in patients taking Arthrem® over the 6-month period.

The company's principal scientist, Dr Sheena Hunt, said that the Otago University studies are a major break-through for osteoarthritis sufferers in whom symptoms usually worsen over time: "Their pain is often poorly managed so there is an urgent need to identify new compounds with anti-inflammatory and analgesic properties, given that current conventional therapies are associated with significant adverse effects."

Promisia's Chief Executive Charlie Daily says although the company receives plenty of anecdotal evidence from customers world-wide who are using the product successfully, having scientific proof is important because the company's point of difference lies in developing and marketing safe and effective natural therapeutic products that are supported by robust scientific research.

For further information, please contact:

Mr Charles Daily, Chief Executive Officer on 04 894 8524 or 021 643 906

ENDS